Altus Pharmaceuticals’ ALTU-237 Enters Phase I Clinical Trial

Altus Pharmaceuticals announced that it has initiated a Phase I clinical trial of ALTU-237, an orally delivered crystalline formulation of an oxalate-degrading enzyme that is being developed for the treatment of hyperoxalurias and the possible prevention of recurrent kidney stones.

The ALTU-237 Phase I clinical trial is a single-center, double-blind, placebo-controlled, dose-escalating study evaluating the safety and tolerability of ALTU-237 in normal, healthy adults, Altus said.

The company added that it plans to randomize 64 subjects into several groups.

According to Altus, a secondary objective of the trial is to determine the clinical activity of escalating dose levels of ALTU-237.